New publication out: SAT in PJI!
🔎 Forty-two studies (n = 2524 patients)
• Practice varies (U.S. vs Europe)
• Success ~70–74%
✔️ Consensus definitions proposed (SAT vs EAT)
Let’s check it out!
https://t.co/IlDu1mMo57
#MSIS#EBJIS#OrthoID#PJI@MSISorg
🔥Just published🔥
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 : Critical Care Medicine #IDXposts https://t.co/jRP9hZFI8W
🆕⚡🟢Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review
Surpassingly only two randomized clinical trials have evaluated tetracyclines for the treatment of BJIs
No single RCT for doxycycline
Most studies are observational #IDXposts
https://t.co/1RxzwVWnIz
🆕💫Nationwide study, in patients with E. faecalis BSI, the six months incidence of colorectal cancer and colorectal neoplasia was low (approximately 0.5% and 2.3%, respectively #IDXposts
https://t.co/L2Wo23s5PD
Fungal endocarditis (FE), a rare but severe subset of infective endocarditis (IE), accounts for 2–4% of cases, with significant morbidity and mortality despite combined clinical and surgical interventions #IEWiki#IDXposts
For those who are interested or who missed it, here's the link:
https://t.co/56Q0RYCK5c
Comments and engagement welcome
Particularly excited about @DrEmilyMcD 's dabi-snap trial getting started soon
🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDXposts
Thanks @Inox94 https://t.co/1KtZVqZ2hg
🆕💫Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes #IDXposts#IEWiki https://t.co/ptlXUivbMh
🆕💫 Retrospective study
Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin as a sequencing treatment* in patients with Gram-positive** chronic prosthetic joint infections #IDXposts#OMWiki
https://t.co/jXf9hhCi0W
🆕🔥State of art review with 🌟s
@JF_Timsit@jasonroberts_pk
Antibiotic therapy for severe bacterial infections
🟢When to start and not to start antibiotics?
🟢Mon vs combo Abx
🟢PK/PD principles
🟢Drug–drug inx
A #mustread article for ID professional
https://t.co/99X5ozFcUk
What the DOTS trial of Staph bacteremia tells us:
• Dalbavancin d1 and d8 vs daily IVs for WEEKS
• No left-sided IE/CNS/prosthetics
• Dalba not superior by DOOR endpoint, but similar clinical outcomes.
Big implications for inpt care. More in link ⬇️⬇️⬇️
🆕💫Antibiotic treatment duration for isolated MSSA native tricuspid valve endocarditis: a standardized multidisciplinary approach( including a CVS ID consult service and multidisciplinary team) #IDXposts#IEWiki@BradSpellberg@DrToddLee@DrEmilyMcD https://t.co/BvT1OXZoJQ
Linezolid-related Optic Nerve Disorders: Insight from a Pharmacovigilance Analysis of the U.S. FDA Adverse Event Reporting System
✅ Just Accepted
https://t.co/EiUh4T334e
🆕🔥Streptococcal endocarditis: a meta-analysis of species dependant risk
🌟Updated figure 🌟Infective endocarditis prevalence of streptococcal species vs. proportion of streptococcal species bacteraemia #IEWiki
https://t.co/fX07lWNrMS